Insider buying last 90 days
No open-market insider purchases were filed for MNKD in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every MNKD insider filing, plotted on the chart in Gekko.Open MNKD in Gekko
NASDAQ: MNKD
MannKind (MNKD) Stock Analysis & Forecast
Oct 12 close
$3.13−0.16 (−4.9%)
Gekko Brief
AI summaryOct 12 closeThis week's move centers on MannKind's clinical data presented at HFSA 2026, highlighting new evidence supporting Furoscix ReadyFlow for outpatient management of edema in heart failure and chronic kidney disease patients. The news carries a positive sentiment, pointing to continued clinical validation for the autoinjector product.
MNKD closed at $3.13, down 4.9%, and sits below both its 50-day average of $3.80 and its 200-day average of $3.91, with the shorter average also below the longer one. The GekkoIndex reads 67.3, placing the stock in the Accumulation zone, up 12.3 over five readings. Price stands 39.6% below Gekko Fair Value of $5.18. One-month return is -16.5%, three-month -19.3%, six-month 18.6%, and one-year -39.1%, against a typical daily move of 7.6% and a typical 20-day move of 9.1%.
Over the next 20 trading days, MannKind's earnings are due 4 November 2026, 23 days away, falling inside that typical holding window; the prior quarter saw an EPS of $0.01 against a $0.02 estimate, with a -3% reaction, and the company has beaten estimates in 3 of the last 8 quarters, averaging a 4.2% absolute reaction. No insider, Congress, or unusual options activity appears in their respective 90-day and 30-day windows. Seasonality over 5 years shows a 6.2% average 20-day return from this point, rising in 3 of those years. Analyst consensus stands at 6 buy ratings, 1 hold, and a $7.84 target.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
MannKind price vs fair value
Close $3.13200-day averageGekko Fair Value $5.18
MannKind quick facts
- Market cap
- $999.7M
- P/E ratio
- —
- Forward P/E
- 25.7
- EPS, TTM
- −$0.14
- Revenue, TTM
- $393.6M
- Profit margin
- -11.1%
- Dividend yield
- —
- Beta
- 1.08
- Volume
- 3.96M avg 5.44M
- 1-year return
- −39.1%
- Typical daily move
- ±7.6%
- Typical 20-day move
- ±9.1%
- 50-day average
- $3.80
- 200-day average
- $3.91
- Next earnings
- Nov 4
- Shares outstanding
- 321.5M
MannKind swing-trade checklist
MannKind scores 3 supportive, 0 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive0 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $3.13 is below the 50-day ($3.80) and 200-day ($3.91) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
67.3, Accumulation
Reading 67.3 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
39.6% below
Price is 39.6% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 23 days
Reports on Nov 4, 2026, 23 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+6.2% on average
From this point in the calendar, the next 20 trading days averaged +6.2% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
MannKind stock chart and price history
MannKind closed at $3.13 on Oct 12, 2026, −39.1% over the past year, inside a 52-week range of $2.23 to $6.51.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −16.5%
- 3 months
- −19.3%
- 6 months
- +18.6%
- 1 year
- −39.1%
The full MNKD chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open MNKD in Gekko
Follow MannKind through every session
Put MNKD on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track MNKD in GekkoFree for 7 days. No credit card required.
About MannKind
MannKind develops medical treatments delivered through the respiratory system, with work centered on endocrine disorders and rare conditions affecting the lungs within the United States. Its most recognized offering is Afrezza, an inhaled form of insulin meant to help adults with diabetes manage their blood sugar levels. The company also sells Thyquidity, a treatment for hypothyroidism marketed to endocrinologists treating both adult and pediatric patients.
Beyond its own product lines, MannKind works with outside partners to extend its research. It has a licensing and partnership arrangement with United Therapeutics Corporation, and it is working alongside NRx Pharmaceuticals on a dry powder version of ZYESAMI, a lab-made form of a naturally occurring peptide studied for its ability to protect cells from inflammation.
MannKind traces its founding back to 1991 and runs its operations from Westlake Village, California. Its shares trade on the NASDAQ under the ticker MNKD.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- mannkindcorp.com
MannKind GekkoIndex: the smart money zone
MannKind’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 67.3, in the Accumulation zone, up 12.3 points over five sessions.
67.3Accumulation
Up 12.3 points over five sessions, from the Neutral zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 51 | +0.7% | −2.1% | ||
| Accumulation (current zone) | 206 | −0.6% | +2.4% | ||
| Neutral | 378 | +1.0% | +1.9% | ||
| Distribution | 43 | −0.4% | +0.5% | ||
| Selling | 4 | Too few readings yet | |||
Average MNKD share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the MNKD price, zone by zone.Track MNKD in Gekko
Is MannKind stock overvalued? Gekko Fair Value
MannKind trades 39.6% below Gekko Fair Value of $5.18, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what MannKind shares are worth, recalculated every trading day.
$5.18
Gekko Fair Value, Oct 10, 2026
39.6% Undervalued
At the end of Aug 2026 the price was 39.2% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open MNKD in Gekko
MannKind insider and Congress trading
No open-market insider purchases were filed for MannKind, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in MNKD were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for MNKD, plotted on the chart in Gekko.Open MNKD in Gekko
Buybacks
MannKind has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $718K
- As a share of market cap
- 0.07%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds MNKD.
0added1opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
MannKind earnings: next date and track record
MannKind reports on Nov 4, 2026 (23 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 4, 2026
23 days away
- EPS estimate
- −$0.06
- Revenue estimate
- $109.5M
3 of 8reports beat the EPS estimate
±4.2%average move across the report
1 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Mar 3, 2026 | $0.01 est $0.02 | — | −3.0% |
| Nov 5, 2025 | $0.03 est $0.01 | $82.13M est $99.85M | +4.0% |
| Aug 6, 2025 | $0.00 est $0.04 | $76.53M est $80.16M | −14.0% |
| May 6, 2025 | $0.04 est $0.06 | $78.35M est $78.44M | −2.2% |
| Feb 25, 2025 | $0.03 est $0.03 | $76.78M est $74.98M | −4.0% |
| Nov 7, 2024 | $0.05 est $0.03 | $70.08M est $74.87M | −1.2% |
| Aug 7, 2024 | −$0.01 est $0.01 | $72.39M est $64.81M | −1.5% |
| May 8, 2024 | $0.04 est $0.03 | $66.26M est $60.49M | −3.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
MannKind stock forecast and analyst price targets
Analysts’ average 12-month price target for MannKind is $7.84, +150.5% from the last close, from 7 firms rating the stock in the last 90 days.
$7.84consensus 12-month target, +150.5% from the last close
Now $3.13Avg $7.84
Low $4.16High $13
Each firm’s latest rating in the last 90 days: 7 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 8 | Truist Financial | $5 | +59.7% |
| Sep 30 | Truist Financial | $6 | +91.7% |
| Sep 21 | H.C. Wainwright | $10 | +219.5% |
| Sep 10 | Leerink Partners | $4.16 | +32.9% |
| Sep 10 | Truist Financial | — | — |
+2.4%average 20-day move after past Accumulation readings
+6.2%average move over the next 20 trading days in the last 5 years
±7.6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
MannKind seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, MannKind averaged +6.2% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.4% | 3 of 5 |
| Next 10 trading days | −0.1% | 3 of 5 |
| Next 15 trading days | +5.6% | 4 of 5 |
| Next 20 trading days | +6.2% | 3 of 5 |
| Next 30 trading days | +5.0% | 3 of 5 |
For scale, MNKD’s typical 20-trading-day move in either direction is about 9.1%.
MannKind market cap and key statistics
MannKind’s market cap is $999.7M and revenue of $393.6M over the last twelve months.
Valuation
- Market cap
- $999.7M
- Forward P/E
- 25.7
- EPS, TTM
- −$0.14
- Gekko Fair Value
- $5.18
Trading
- Volume
- 3.96M
- Avg volume, 20 days
- 5.44M
- 52-week high
- $6.51
- 52-week low
- $2.23
- Shares outstanding
- 321.5M
Financials
- Revenue, TTM
- $393.6M
- Profit margin
- -11.1%
- Return on equity
- 0%
- Quarterly earnings growth, YoY
- −34.9%
Risk and income
- Beta
- 1.08
- Typical daily move
- ±7.6%
- Typical 20-day move
- ±9.1%
MannKind stock news this week
1 headline about MannKind from the past week, newest first, each linking to the publisher.
MannKind peers
MannKind’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
MannKind stock FAQ
What is MannKind’s market cap?
MannKind’s market cap is $999.7M at the Oct 12, 2026 close of $3.13, with 321.5M shares outstanding.
What is the MannKind stock forecast?
The consensus analyst 12-month price target for MannKind is $7.84, +150.5% from the last close. Of the 7 firms that rated the stock in the last 90 days, 6 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is MannKind stock overvalued or undervalued?
On Gekko’s estimate MannKind is undervalued: the Oct 12, 2026 close of $3.13 is 39.6% below Gekko Fair Value of $5.18. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does MannKind report earnings next?
MannKind is expected to report on Nov 4, 2026 (23 days away). Analysts expect earnings of −$0.06 per share on revenue of $109.5M. MannKind beat the earnings estimate in 3 of its last 8 reports, moving 4.2% on average across the report.
What is MannKind’s 52-week high and low?
MannKind’s 52-week high is $6.51 and its 52-week low is $2.23; it closed at $3.13 on Oct 12, 2026, −39.1% over the past year. Over the last five years the shares peaked at $7.63 on Nov 6, 2024.
Is MannKind stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and seasonality) and 2 as headwinds (trend and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See MannKind the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.